Feasibility of azithromycin prophylaxis during a pertussis outbreak among healthcare workers in a university hospital in Paris

Infection Control and Hospital Epidemiology

Volumn 27, Issue 6, 2006, Pages 626-629

  Giugliani, Camila ^a,b   Vidal Trécan, Gwenaëlle ^a,b   Traore, Souleymane ^a   Blanchard, Hervé ^a   Spiridon, Gabriela ^a   Rollot, Florence ^a,b   Launay, Odile ^a,b   Gorodestski, Myriam ^a   Marande, Jean Luc ^a   Vinsonneau, Christophe ^a   Guillevin, Loïc ^a,b   Salmon Céron, Dominique ^a,b  

^a AP HP ^*  (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG TOLERABILITY; EPIDEMIC; FEASIBILITY STUDY; FEMALE; FRANCE; HEALTH CARE PERSONNEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PERTUSSIS; UNIVERSITY HOSPITAL; UNSPECIFIED SIDE EFFECT;

ADULT; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; AZITHROMYCIN; DISEASE OUTBREAKS; DISEASE TRANSMISSION, HORIZONTAL; FEASIBILITY STUDIES; FEMALE; FRANCE; HEALTH PERSONNEL; HOSPITALS, UNIVERSITY; HUMANS; MALE; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; WHOOPING COUGH;

EID: 33745771582     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/505102     Document Type: Article

References (20)

1. Christie CD, Marx ML, Marchant CD, Reising SF. The 1993 epidemic of pertussis in Cincinnati: resurgence of disease in a highly immunized population of children. N Engl J Med 1994; 331:16-21.
2. Guris D, Strebel PM, Bardenheier B, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis 1999; 28:1230-1237.
3. Gilberg S, Njamkepo E, Du C, et al. Evidence of Bordetella pertussis infection in adults presenting with persistent cough in a French area with very high whole-cell vaccine coverage. J Infect Dis 2002; 186:415-418.
4. Aoyama T, Harashima M, Nishimura K, Saito Y. Outbreak of pertussis in highly immunized adolescents and its secondary spread to their families. Acta Paediatr Jpn 1995; 37:321-324.
5. von Konig CH, Halperin S, Riffelmann M, Guiso N. Pertussis of adults and infants. Lancet Infect Dis 2002; 2:744-750.
6. Nelson JD. The changing epidemiology of pertussis in young infants: the role of adults as reservoirs of infection. Am J Dis Child 1978; 132: 371-373.
7. Wright SW, Decker MD, Edwards KM. Incidence of pertussis infection in healthcare workers. Infect Control Hosp Epidemiol 1999; 20:120-123.
8. Ward A, Caro J, Bassinet L, Housset B, O'Brien JA, Guiso N. Health and economic consequences of an outbreak of pertussis among healthcare workers in a hospital in France. Infect Control Hosp Epidemiol 2005; 26:288-292.
9. Martinez SM, Kemper CA, Haiduven D, Cody SH, Deresinski SC. Azithromycin prophylaxis during a hospitalwide outbreak of a pertussis-like illness. Infect Control Hosp Epidemiol 2001; 22:781-783.
10. Bassinet L, Matrat M, Njamkepo E, Aberrane S, Housset B, Guiso N. Nosocomial pertussis outbreak among adult patients and healthcare workers. Infect Control Hosp Epidemiol 2004; 25:995-997.
11. Forsyth KD, Campins-Marti M, Caro J, et al. New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative. Clin Infect Dis 2004; 39:1802-1809.
12. Rapport du Conseil Supérieur d'Hygiène Publique de France, Section Maladies Transmissibles: relatif à la conduite à tenir devant un ou plusieurs cas groupés de coqueluche. Direction Générale de la Santé; 2004 Jan 16.
13. Hewlett EL, Edwards KM. Clinical practice: pertussis-not just for kids. N Engl J Med 2005; 352:1215-1222.
14. Tiwari T, Murphy TV, Moran J. Recommended antimicrobial agents for treatment and postexposure prophylaxis of pertussis. National Immunization Program, Centers for Disease Control and Prevention. MMWR Recomm Rep 2005; 4(RR-14):1-16.
15. Hopkins SJ. Clinical toleration and safety of azithromycin in adults and children. Rev Contemp Pharmacother 1994; 5:383-389.
16. Ruuskanen O. Safety and tolerability of azithromycin in pediatric infectious diseases: 2003 update. Pediatr Infect Dis J 2004; 23(2 Suppl):S135-S139.
17. Macaigne G, Mokbel M, Marty O, De La LP, Mallet L. Acute pseudoangiocholitic hepatitis probably induced by azithromycin [in French]. Gastroenterol Clin Biol 2000; 24:969-970.
18. Suriawinata A, Min AD. A 33-year-old woman with jaundice after azithromycin use. Semin Liver Dis 2002; 22:207-210.
19. Purcell BK, Dooley DP, Gray PJ, Hill KJ, Oliverson FW. Experience with directly observed prophylaxis using erythromycin in military trainees exposed to pertussis. Mil Med 2004; 169:417-420.
20. Anastasio GD, Little JM, Jr., Robinson MD, Pettice YL, Leitch BB, Norton HJ. Impact of compliance and side effects on the clinical outcome of patients treated with oral erythromycin. Pharmacotherapy 1994; 14:229-234.